Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway.

Bitonti AJ, Dumont JA.

Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):1106-18. Epub 2006 Aug 12. Review.

PMID:
16997417
2.

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.

Dumont JA, Low SC, Peters RT, Bitonti AJ.

BioDrugs. 2006;20(3):151-60. Review.

PMID:
16724863
3.

Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis.

Low SC, Nunes SL, Bitonti AJ, Dumont JA.

Hum Reprod. 2005 Jul;20(7):1805-13. Epub 2005 Apr 7.

PMID:
15817590
4.

Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, Yamaguchi T.

J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18.

5.

Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway.

Dumont JA, Bitonti AJ, Clark D, Evans S, Pickford M, Newman SP.

J Aerosol Med. 2005 Fall;18(3):294-303.

PMID:
16181004
6.

Clinical perspectives on pulmonary systemic and macromolecular delivery.

Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R.

Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):996-1008. Epub 2006 Aug 12. Review.

PMID:
16996638
7.

Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway.

Bitonti AJ, Dumont JA, Low SC, Peters RT, Kropp KE, Palombella VJ, Stattel JM, Lu Y, Tan CA, Song JJ, Garcia AM, Simister NE, Spiekermann GM, Lencer WI, Blumberg RS.

Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9763-8. Epub 2004 Jun 21.

8.

Expression and characterization of human growth hormone-Fc fusion proteins for transcytosis induction.

Lee CH, Woo JH, Cho KK, Kang SH, Kang SK, Choi YJ.

Biotechnol Appl Biochem. 2007 Apr;46(Pt 4):211-7.

PMID:
17067288
9.

Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology.

Huang C.

Curr Opin Biotechnol. 2009 Dec;20(6):692-9. doi: 10.1016/j.copbio.2009.10.010. Epub 2009 Nov 4. Review.

PMID:
19889530
10.

In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery.

Sakagami M.

Adv Drug Deliv Rev. 2006 Oct 31;58(9-10):1030-60. Epub 2006 Aug 15. Review.

PMID:
17010473
11.

Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.

Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M.

Glycobiology. 2007 Jan;17(1):104-18. Epub 2006 Sep 29. Erratum in: Glycobiology. 2007 Oct;17(10):1030.

PMID:
17012310
12.

Pulmonary administration of interferon Beta-1a-fc fusion protein in non-human primates using an immunoglobulin transport pathway.

Vallee S, Rakhe S, Reidy T, Walker S, Lu Q, Sakorafas P, Low S, Bitonti A.

J Interferon Cytokine Res. 2012 Apr;32(4):178-84. doi: 10.1089/jir.2011.0048. Epub 2011 Dec 22.

PMID:
22191463
13.

The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.

Rogueda PG, Traini D.

Expert Opin Drug Deliv. 2007 Nov;4(6):595-606. Review.

PMID:
17970663
14.

Pulmonary drug delivery: medicines for inhalation.

Henning A, Hein S, Schneider M, Bur M, Lehr CM.

Handb Exp Pharmacol. 2010;(197):171-92. doi: 10.1007/978-3-642-00477-3_6. Review.

PMID:
20217530
15.

Quantitative methods for developing Fc mutants with extended half-lives.

Kamei DT, Lao BJ, Ricci MS, Deshpande R, Xu H, Tidor B, Lauffenburger DA.

Biotechnol Bioeng. 2005 Dec 20;92(6):748-60.

PMID:
16136591
16.

Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.

Gurbaxani B, Dela Cruz LL, Chintalacharuvu K, Morrison SL.

Mol Immunol. 2006 Mar;43(9):1462-73. Epub 2005 Sep 1.

PMID:
16139891
17.

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC.

Int Immunol. 2006 Dec;18(12):1759-69. Epub 2006 Oct 31.

PMID:
17077181
18.
19.

The influence of pulmonary surfactant on nanoparticulate drug delivery systems.

Schleh C, Rothen-Rutishauser B, Kreyling WG.

Eur J Pharm Biopharm. 2011 Apr;77(3):350-2. doi: 10.1016/j.ejpb.2010.12.025. Epub 2010 Dec 31.

PMID:
21195761
20.

Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis.

Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, Senices M, Wu PW, Sibley B, Leathurby Y, Brown TP, Nickerson-Nutter C, Keith JC Jr, Collins M.

Arthritis Rheum. 2007 Apr;56(4):1152-63.

Supplemental Content

Support Center